Baltimore, MD, United States of America

Chul-Kee Park


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2019

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Chul-Kee Park: Innovator in Cancer Treatment

Introduction

Chul-Kee Park is a notable inventor based in Baltimore, MD (US). He has made significant contributions to the field of cancer research, particularly in the area of treatment and patient survival prediction. His innovative work has led to the development of a patented method that utilizes the ZMIZ1 marker.

Latest Patents

Chul-Kee Park holds a patent titled "Use of the ZMIZ1 marker in directing treatment and predicting survival in cancer." This invention provides methods and compositions for treating cancer and predicting patient survival. In one embodiment, the method involves obtaining a biological sample from the patient and detecting hypermethylation of ZMIZ1 using primers that specifically bind to CpG island 139 at the alternative promoter of the ZMIZ1 gene. He has 1 patent to his name.

Career Highlights

Chul-Kee Park is affiliated with The Johns Hopkins University, where he continues to advance his research in cancer treatment. His work is recognized for its potential impact on improving patient outcomes in oncology.

Collaborations

Chul-Kee Park has collaborated with esteemed colleagues, including Dimitrios Mathios and Michael Lim. Their combined expertise contributes to the innovative research being conducted at The Johns Hopkins University.

Conclusion

Chul-Kee Park is a dedicated inventor whose work in cancer treatment exemplifies the importance of innovation in medical research. His contributions are paving the way for advancements in patient care and survival prediction.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…